Literature DB >> 20014922

Discovery of prostate cancer biomarkers by microarray gene expression profiling.

Karina Dalsgaard Sørensen1, Torben Falck Ørntoft.   

Abstract

Prostate cancer is the most commonly diagnosed malignancy in males in the Western world. This review focuses on advances in biomarker discovery for prostate cancer by microarray profiling of mRNA and microRNA expression. Novel biomarkers are strongly needed to enable more accurate detection of prostate cancer, improve prediction of tumor aggressiveness and facilitate discovery of new therapeutic targets for tailored medicine. Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail. In addition, a compilation of prognostic gene expression signatures for prediction of prostate cancer patient outcome is provided, and their possible clinical utility is discussed. Furthermore, limitations in the application of microarray-based expression profiling for identification of prostate cancer biomarkers are addressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014922     DOI: 10.1586/erm.09.74

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  29 in total

Review 1.  Ten questions about systems biology.

Authors:  Michael J Joyner; Bente K Pedersen
Journal:  J Physiol       Date:  2011-01-04       Impact factor: 5.182

2.  Identifications of genetic differences between metastatic and non-metastatic osteosarcoma samples based on bioinformatics analysis.

Authors:  Baoyong Sun; Fangxin Wang; Min Li; Mingshan Yang
Journal:  Med Oncol       Date:  2015-04-02       Impact factor: 3.064

Review 3.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

4.  Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network.

Authors:  Medha Darshan; Qizhi Zheng; Helen L Fedor; Nicolas Wyhs; Srinivasan Yegnasubramanian; Peng Lee; Jonathan Melamed; George J Netto; Bruce J Trock; Angelo M De Marzo; Karen S Sfanos
Journal:  Prostate       Date:  2013-09-21       Impact factor: 4.104

5.  Prostate-specific antigen: its relationship with alcohol intake and tobacco.

Authors:  Jorge D Escandriolo Nackauzi; Raúl H Colla; Graciela R Ravazzani; María I Gaido; Patricia Bertolotto; Adriana B Actis
Journal:  Med Oncol       Date:  2011-04-12       Impact factor: 3.064

Review 6.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

Review 7.  Multiscale integration of -omic, imaging, and clinical data in biomedical informatics.

Authors:  John H Phan; Chang F Quo; Chihwen Cheng; May Dongmei Wang
Journal:  IEEE Rev Biomed Eng       Date:  2012

Review 8.  Biomarkers for colorectal cancer.

Authors:  Takuji Tanaka; Mayu Tanaka; Takahiro Tanaka; Rikako Ishigamori
Journal:  Int J Mol Sci       Date:  2010-09-13       Impact factor: 5.923

9.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Authors:  R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

Review 10.  Multiplexed detection of molecular biomarkers with phase-change nanoparticles.

Authors:  Ming Su
Journal:  Nanomedicine (Lond)       Date:  2013-02       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.